Aarti Drugs Limited (524348) Earnings Call Transcript
November 4, 2026
Earnings Call Speaker Segments
Good day, ladies and gentlemen, and welcome to the Q2 and H1 FY '27 earnings conference call for Aarti Drugs Limited. <<operator_script>> Kindly be aware that this conference is being recorded. Before we start, here's a quick disclaimer. This call may include forward-looking statements regarding the company, and those are based on the beliefs, opinions and expectations held by the company as of today's date. Such statements do not guarantee future performance and may involve risks and uncertainties that are hard to predict. I'll now turn the conference over to Mr. Adhish Patil, Managing Director of Aarti Drugs Limited. Thank you, and over to you, sir.
Thank you. Good morning, everyone, and thanks for being with us on the earnings conference call for Aarti Drugs Limited covering the second quarter and first half of FY '27. Joining me today are Mr. Harshit Savla, our Joint Managing Director; Mr. Harit Shah, Whole-Time Director; Mr. Vishwa Savla, Managing Director of Pinnacle Life Science Private Limited; and SGA, our investor relations adviser. The results and investor presentation for the quarter ended 30th September, 2026 have been filed with the stock exchanges and can also be found on our website. I hope you have had an opportunity to review them. I am happy to share that Q2 FY '27 has been a milestone quarter for Aarti Drugs Limited. For the first time ever, total consolidated revenue for a single quarter stood at INR 829 crores, which is 27% higher than a year ago. The operating environment stayed supportive throughout the quarter. Developments in West Asia kept API prices firm across the industry, while customers increasingly prioritized reliable and uninterrupted supply of APIs. Aarti Drugs was well positioned to benefit from this, delivering a 16% improvement in realizations year-on-year, alongside a volume growth of 5%. Just as important as the recovery in our margins, EBITDA grew 63% to INR 138 crores, the highest quarterly EBITDA we have ever reported, with our EBITDA margin for the quarter reaching 16.6%, up 370 basis points year-on-year basis and the highest we have achieved in nearly 6 years.
Profit after tax climbed 83%, reaching INR 82.8 crores. We're keeping our attention squarely on the things we can control — that means pushing volumes higher, sharpening both our product mix and market mix, and bringing costs down via backward integration, process improvement and energy optimization. Our API business, still our biggest segment, expanded 17% to INR 605 crores, up from INR 516 crores in Q2 FY '26. Specialty Chemicals kept scaling up, helped along by our Sayakha facility, and it grew 92% to INR 72 crores versus INR 37 crores a year ago. Formulations also delivered a great quarter, up 58% from INR 82 crores in Q2 FY '26 to INR 130 crores in Q2 FY '27, driven by exports, which climbed 73% year-on-year. Now, on to a few projects. I'll start with the methylamines plant at Sayakha. Through the quarter, that facility ran at roughly 72% utilization, and captive consumption of our antidiabetic portfolio came in at about 85%. These improvements in product mix, backward integration and cost efficiency are structural — they'll remain with us even as pricing conditions normalize down the road. I want to point out just how fast this facility has come together.
We commissioned it in September last year, and within roughly a year, a large share of our key intermediates for metformin — which we previously purchased from outside — is now produced in-house. That gives us improved control over cost, quality and availability of inputs for one of our most important products, and it strengthens our standing as a dependable, integrated supplier to our customers. We're now working on improving utilization of the other products at that site as well. At the Tarapur facility, the improvements we mentioned earlier are now underway, and we've also begun producing technical-grade methyl salicylate. We have manufactured roughly around 85 tonnes so far in the last quarter. We're also expanding our USFDA approved block at Tarapur by constructing an adjacent block, which will more than double its capacity. This expansion includes 3 new multipurpose plants, which will give us the flexibility to make a wider range of products for regulated markets. We expect the project to take around 18 to 20 months, with commercial production targeted towards the end of FY '29. At Sarigam, we're increasing our metformin capacity from 1,400 tonnes per month to 1,700 tonnes per month, with commercialization planned in early FY '28.
On top of that, by the close of FY '28 we're bringing in a committed 500 tonnes per month block that is USFDA compliant. Also, our USFDA DMF for metformin is currently being prepared. Over at our Baddi facility in Himachal Pradesh, a brownfield expansion is underway; it uses the plot next door so that we can roughly double the existing oral solid dosage production capacity and back a long-term formulations revenue goal. With a more robust, better integrated platform and additional capacity lined up at Tarapur, Sarigam and Baddi, we head into the year's second half with confidence. Approval of this block is expected to unlock access to a large number of customers in the U.S. and EU markets. I'd also like to give an update on our sustainability efforts. CRISIL has given Aarti Drugs an ESG rating of 61 for FY '25, '26, which puts us in the strong category. To us, that reflects the consistent work our teams have done on environment, safety and governance at our sites, and we'll keep building on it. With that, I'll walk you through our financial performance. To begin, we'll cover the consolidated financial highlights for Q2 FY '27. Revenue came in at INR 829 crores, versus INR 653 crores in Q2 FY '26, a 27% Y-o-Y increase.
EBITDA came in at INR 138 crores, compared with INR 84 crores in Q2 FY '26, which works out to 63% growth YoY. The EBITDA margin was 16.6%, an expansion of 370 basis points on a Y-o-Y basis. PAT was INR 83 crores against INR 45 crores in Q2 FY '26, a rise of 83% Y-o-Y. The PAT margin came to 10%, an expansion of 310 basis points Y-o-Y. Now let's talk about the standalone business for Q2 FY '27. Revenue was INR 709 crores versus INR 579 crores in Q2 FY '26, up 22% year-on-year. The standalone business accounted for 84.3% of consolidated revenue. Of standalone revenue, 68% was from the domestic market and 32% from exports. Domestic revenue rose 43% Y-o-Y, whereas export revenue fell 5% Y-o-Y. In the API segment, the antibiotic therapeutic category made up 34.1%; antidiabetic, 18.2%; antiprotozoal, 18.1%; antiinflammatory, 14.8%; antifungal, 9.3%; and the remainder accounted for 5.6% of total API sales. Consolidated financial highlights, H1 FY '27. Turning to the first half, revenue was INR 1,532 crores compared with INR 1,244 crores in H1 FY '26, a gain of 23% Y-o-Y. EBITDA came to INR 235 crores versus INR 158.8 crore in H1 FY '26, a growth of 48% Y-o-Y.
Our EBITDA margin came in at 15.3%, which is an expansion of 250 basis points year over year. PAT was INR 133 crores, versus INR 99 crores in H1 FY '26, representing 34% growth year over year. The PAT margin was 8.7%, an expansion of 70 basis points year over year. Now let's discuss our formulations segment. Lastly, our formulation business, which we operate through our subsidiary Pinnacle Life Science, posted revenue of INR 130 crores in Q2 FY '27 against INR 83 crores in Q2 FY '26, up 58% year over year. Exports made up 74% of this formulation revenue. For H1 FY '27, formulation revenue was INR 212 crores versus INR 163 crores in H1 FY '26, up 30%, with exports representing 63% of total formulation sales. With that, I'd now like to open the floor for questions. Thank you.
<<operator_script>> Our first question comes from Candice Pereira at Dolat Capital.
My first question concerns the API business. We saw 17% growth this quarter. So how much came from pricing and how much from volume growth?
I apologize, Candice, but could you say that question again? I didn't catch it.
Yeah, so when it comes to the API business, how much of that growth comes from price versus how much comes from volume?
Right, yes. So on a year-over-year basis for the API business, we saw pricing rise by roughly 17% to 18%, and there was volume growth as well — I'm speaking on the overall stand-alone basis here — and for API and Spec Chem combined, overall volume growth came in at about 5%.
And for the first half of H1, did it stay within that same range?
Looking back at Q1, as I recall, volume increased by roughly 3%, while rate was up approximately 16% to 17% year over year in that first quarter.
And what about the rate variance?
Right, so for the first half, the rate variance should land somewhere around 17% to 18%.
Alright, 17% to 18%. And the formulations business also saw pretty strong growth this quarter. So was there anything one-off in there?
Vishwa, do you want to take this question?
Right, of course. Essentially, that expansion has come from a rise in our export operations, something we've focused on over the past few years by opening up additional markets, and we have products under registration across a range of regulated and emerging markets. That's why we've now begun commercializing products in new territories, and that is what has driven the growth in both revenue and EBITDA margin. So although this quarter was an exceptional one, we believe that with our entry into new markets and new products, we'll be able to maintain a similar level of revenue.
So we can count on this revenue level holding up through the remainder of the year, is that right?
Okay.
Alright, so about our margins right now — given that this pace of growth in formulations can be sustained, will our margins hold up at 15% as well, the level we're seeing in the first half of the year?
Is your question about consol margins?
Company margins across the board.
Right. On company-wide margins overall, our view is that 15% ought to be sustainable. That said, in this specific quarter we came in at EBITDA margins of roughly 16.6%.
Yeah. All right, and what about gross margins as well?
Regarding gross margins, here's what's occurred: in this business there's a cost-plus formula, and when API and Spec Chem rates rise, typically the gross contribution goes up in absolute terms, yet the gross contribution margin falls due to the base effect when those rates climb substantially. At the same time, though, manufacturing overheads will decline as a percentage. So overall, EBITDA margins ought to hold steady.
<<operator_script>> Our following question comes from Ankur Kumar at Alpha Capital.
Sir, as far as splitting that between volume and pricing goes, you mentioned that 17% to 18% is pricing growth. Did I get that right, sir?
Yes.
So how do we see it for this quarter and the one after — does this level of volume growth, and this level of pricing growth, hold up? Or what's our thinking there?
Right now, pricing is still holding steady, since several factors are at play. When the war began in March, the price increases were tied more to gas-based products — those made from natural gas. Going forward, crude will also push pricing higher, across whatever products are linked to crude prices either directly or indirectly. So our sense at this point is that, for sales, pricing stays where it is.
Understood, sir. And on that point, sir, you're mentioning 15% as a sustainable margin, yet this quarter came in at 16%. So was there any benefit tied to inventory during this quarter? Or what's behind the expectation of some moderation?
Yes. Look, we're simply taking a cautious stance here. Now, the point is, for the stand-alone company, if you go back over the last 2 quarters, we consistently exceeded 14% in each one of those quarters on a stand-alone basis. But on the formulation side, in this particular quarter, we achieved exceptional EBITDA margins of roughly around 28%, thanks to strong export orders. To be candid, we do have visibility of almost -- we have pending -- export pending orders covering almost 4 months more. For more than 1 quarter, we do have export orders. But we're simply being cautious that even if, on a longer-term steady-state basis, even if formulation margins were to decline to, let's say, 20%, even then, assuming formulation would going forward account for around 15%, 16% of consol revenue and the stand-alone business would be roughly around 84%, 85% of consol revenue at 14%, even then we would be able to deliver slightly upwards of 15% margin. That said, we do have room to improve EBITDA margins at the stand-alone level as well.
Understood, sir. And as for that 28% margin on the formulation, will it hold up for 4 months, and after that will we need additional orders for it?
Yes. So assuming orders continue to arrive, we ought to be able to keep that at least around the low 20% range.
Right. And we think that beyond that 4-month order book, now that we've got access into several markets with several products, we expect this sort of export momentum to keep going on the formulation side.
Understood, sir. And sir, regarding the API side, what sort of volume growth should we expect as we head into the second half?
To be candid, at the start of the year we were aiming for volume growth of roughly 10% or so at the company level. In the first half, however, we managed only 3% and 5% volume growth, respectively, in the stand-alone segment. The main reason is that prices for all specialty chemicals and APIs have risen. Usually, the purchasing teams on the formulation side try to avoid overstocking product because prices have jumped suddenly for geopolitical reasons. So there is a waiting game here. Once they begin to believe this is a new normal, then volume growth and demand should start to come in. In that case, we can expect, say, high single-digit volume growth. But as of now, even we are not that sure. So, say, we will assume volume growth somewhere between 5% to 10%.
<<operator_script>> Our following question comes from Akash, who is an individual investor.
I'd like to understand what the company's aspiration or vision is for shifting toward complex APIs instead of volume-driven ones, say from 2030 onward. Is management intending to move toward handling complexity problems — the really complex APIs in manufacturing? So I want to hear about your vision regarding API complexity.
Yes. Thanks for that. That's actually a really interesting question. So, as you know, Aarti Drugs has traditionally always been strong in bulk volume APIs, thanks to our engineering and process improvement strengths. So going forward, we're actually working on our business plan for the next — you could say — 5 to 7 years, and that includes bringing in newer molecules — a mixed bucket of molecules. Some would be similar to what we do, where our strength lies. Some would be somewhat more niche molecules, natives. And we're also trying to build competencies on a CDMO platform. So for that, strengthening our R&D further and our ability to carry out more complex situation. So we're thinking along those lines. So probably within 4, 5 months, we'll have a clearer picture of what the CapEx or capital assignment toward these kinds of projects will be. But definitely, if you ask on a 3 to 5 years horizon, so we'll be working in that direction. And apart from that, one more thing we're doing in parallel is that we're trying to increase our regulatory presence — meaning basically trying to increase presence in regulated markets for our existing molecules.
For most of the molecules we already have, we may be cost leaders, yet we mainly serve the ROW market and, to some degree, the regulatory market. Still, we want to expand that footprint in the regulated market, which would push our margins higher and make them more stable too.
<<operator_script>> Our following question comes from Resham Jain at VVD Asset Managers.
And congratulations on being promoted to Managing Director of the company. So I have a few questions. The first one concerns the formulation business. In earlier calls, we mentioned oncology and the USFDA approval. And you said that USFDA-related dossier filing is also underway at the formulation facility. Did that also contribute during this quarter, or is that still to come?
That part hasn't happened yet. Right. Vishwa is able to clarify.
Sure, I’ll address that. So this quarter we do have a modest contribution coming from the U.S. oncology product, though right now it’s quite limited since the launch happened only very recently. As a result, we’re expecting U.S. revenue to grow over the next 3 to 6 months with the single product we currently have on the market. Beyond that, we have one more ANDA that should receive approval within the next few months. We also have plans to file another 4 to 5 oncology products over the rolling 12 months. So the U.S. business has now begun, but it still has to be scaled up to a meaningful level.
Got it. And your annual report referred to the goal of growing the formulation business to INR 1,000 crores. Given the momentum you've seen in Q2 and probably in Q3, as you said, with the order book, do you think that INR 1,000 crore ambition could be reached much sooner than that? Because traction of this kind hasn't been seen in the last few years.
Okay, so yes — that's the belief we hold: we think we can hit the INR 1,000 crore landmark sooner than what we've published. And we're also expanding our capacities. We had reached a point where our capacities were essentially operating at full scale. So as Adhish said, a brownfield expansion is underway, and by the middle of next year it should double our capacities. Combined with better utilization of our oncology facility — which right now has only 1 or 2 products commercialized — once that ramps up, and we see that happening in the very near future, we will definitely be able to reach the INR 1,000 crore mark.
Oncology would also come with a higher margin profile.
Correct. If you look at it on a gross basis, margins in oncology ought to come in a bit above what our existing business delivers.
Understood. Regarding the second question, it concerns salicylic acid. Is there any news on the antidumping duty front? That issue was, in a sense, a difficulty for us.
Harshit bhai, would you be willing to take this question?
Yes. It'll go in with the September report. So we need to submit 9 months of data on top of that. Once these results are out, we'll file the antidumping duty submission then. For the antidumping duty, they require additional data — 9 months' worth.
All right, then — at what point will DGTR, or anyone else for that matter...
During our first meeting, they framed it this way -- they'll kick things off ahead of year-end, in December.
All right, all right. So perhaps another 6 months or so will be needed, since following that, 90 days will be consumed by the Ministry of Finance.
Yes, right. To start with, they'll kick things off, and after that they'll need an additional 3- to 6-month stretch before they're fully into it.
All right. Understood. This final question goes to Adhish. The cash we're generating at present, and nearly all the capital expenditures we've taken on across the last 3, 4 years, are basically finished. What's the plan from here? You did bring up the 5, 7 year vision that you intend to set out. But yearly cash generation is significant at this point. So with that in mind, what does the CapEx plan look like for '27 and '28?
Yes. So in the first half, we just about hit roughly close to INR 90 crores of operating cash flow across both companies — that's stand-alone and formulation. And it was pretty much even between the stand-alone business and the formulation business. And going forward, for the stand-alone business, as we mentioned, we'll be proceeding with the expansion of the USFDA block by adding 3 more lines. On a full-scale basis, that can carry a revenue potential of anywhere from INR 180 crores to INR 200 crores. It's going to be a multipurpose facility. On top of that, we're expanding our metformin capacities, and we're making those USFDA compliant too. So both of these projects are targeted at regulatory markets — and mainly, we see sufficient business coming from our existing molecules as such. So the chemistry is already known to us. That said, we'll also be bringing in newer products, more niche products, into our multipurpose USFDA block. And a few months from now, we'll have a few more CapEx plans ready. One is setting up a CDMO block for intermediates and Spec Chem. And we also intend to invest quite heavily in R&D within the formulation division as well.
Our next question comes from Jay Jain with JJ Capital.
Sir, congratulations on those excellent results. Sir, during your remarks you brought up realization gain, and we're aware that certain API and KSM prices rose sharply once the conflict started. Sir, how quickly can we pass along these higher prices? And also, if you could quantify what portion of your Q2 realization gain stems from contracts signed when prices peaked, and how much of it resets should crude prices fall in H2 FY '26?
Sure. Let me give you a broad picture of where our order books stand. In exports, we usually carry pending orders worth about 2.5 to 3 months, while in the domestic market it's a bit under 1 month — call it 1 month on average. Those are the prices that get locked in going forward. That said, any time input costs rise — whether raw materials or intermediates — every new contract is negotiated at the higher rates. So when it comes to passing on prices, that happens quite fast for new orders we book from that point on. It's only the pending orders where we still have to supply those materials at the lower rate. At the same time, we also keep RM inventory of about 40, 50 days. So part of that risk gets mitigated through our inventories. Still, I can't give you an exact quantification, because with so many products in our portfolio, it's hard for me to put a number on it...
Understood. One more thing, since you brought up raw materials — from here on out, should we be building up inventory or raw materials to a greater degree?
No. Ideally, we shouldn’t, since prices are elevated. My view is that we ought to run things so that raw material bookings line up with sales bookings rather than making a speculative call. If we do take a call and the market reverses direction, the losses could be very large.
Understood. Sir, only one final question from me. Could you help us get a sense of how much of the contribution to EBITDA margin has come from changes in product mix as opposed to operational efficiency and pricing benefit?
All right. So when we look at our stand-alone business, which accounts for roughly 84% of total consolidated revenues, some portion of the gains there has come from operational energy optimizations. We've taken on a few projects. As a matter of fact, additional projects are coming up, such as our solar projects. So those will begin contributing too in this quarter — that is, the December quarter. And so the gross contribution level has risen as well, there's no question about it. So I'd say perhaps around 50 basis points could be attributable to the higher overall gross contribution, with the remainder coming from reduced manufacturing cost. And as far as formulations go, it's primarily a matter of gross contribution.
<<operator_script>> Our following question comes from Rohit with SK Security and Services.
Nice work on those numbers. I just have the one question. For the oncology segment, I'd appreciate a bit more detail — things like which product molecules you're going after, the kind of client profiles you're aiming to work with, and perhaps which geographies and timelines are involved? Also, what kind of contribution to our revenue might we see by FY '29 or '30?
When we look at how much oncology will add to revenue at, say, an FY '30 level, our estimate is somewhere between the late 30s and maybe the early 40%. And really, for us, the oncology portfolio is made up of roughly 25 to 30 molecules, sitting at different stages of development and filing. A lot of those are existing APIs that our group companies already manufacture. So essentially, these are the nib families and cyclic families of oncology oral solids. And in some countries we handle our own filings, while in other markets it's a B2B-driven model, where we partner with most of the leading players in those markets.
Understood, sir. And how about by geography?
As we said, we're essentially examining the whole regulated market landscape — the U.S., EU, U.K., and Latin America, the Middle East, and Asian markets. So that's a broad global strategy.
Since no one else has a question, I'll turn the conference back to management for their closing remarks. Sir, the floor is yours.
Thanks to all of you for being with us on today's earnings call. We're grateful for your interest and for every question you raised about Aarti Drugs' financial results and what lies ahead for us. Should you have any additional questions, please reach out to SGA, our investor relations adviser. Thank you, and we wish you a happy Diwali.
Much appreciated. That brings us to the end of this call for Aarti Drugs Limited. We're grateful you took part, and you can go ahead and hang up now. Thanks again.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Aarti Drugs Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Aarti Drugs Limited earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.